Panitumumab-Induced Paronychia: A Case Report and a Brief Review of the Literature.
Adverse reaction
Metastatic colon cancer
Nail
Panitumumab
Paronychia
Journal
Skin appendage disorders
ISSN: 2296-9195
Titre abrégé: Skin Appendage Disord
Pays: Switzerland
ID NLM: 101670617
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
21
08
2020
accepted:
04
10
2020
entrez:
2
4
2021
pubmed:
3
4
2021
medline:
3
4
2021
Statut:
ppublish
Résumé
Panitumumab is a recombinant, fully humanized IgG2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). Panitumumab is indicated for patients with metastatic colorectal cancer with progressive refractory disease. Targeted therapies are well known to be well tolerated; however, they may induce toxicities that are distinct from those of classical chemotherapeutic agents. For instance, EGFR inhibitors (EGFRIs) are associated with some specific dermatological adverse effects, one of which is nail toxicity. Since panitumumab is fully humanized, unlike most of the other EGFRIs, it has been reported to have reduced incidence of adverse reactions. Nail-related adverse effects are frequently observed with EGFRIs. A literature search has yielded a list of reviews describing panitumumab-induced nail toxicity. However, as far as we know, there is no case report detailing this adverse effect of panitumumab. Here, we present a case of panitumumab-induced paronychia in a 60-year-old woman with metastatic colon cancer. With this case report, we would like to review the literature and discuss the possible underlying mechanisms of this condition.
Identifiants
pubmed: 33796558
doi: 10.1159/000512036
pii: sad-0007-0123
pmc: PMC7991612
doi:
Types de publication
Case Reports
Langues
eng
Pagination
123-126Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
Curr Oncol. 2010 Jul;17 Suppl 1:S18-30
pubmed: 20680104
J Am Acad Dermatol. 2015 Feb;72(2):203-18; quiz 219-20
pubmed: 25592338
J Clin Oncol. 2007 May 1;25(13):1658-64
pubmed: 17470858
J Am Acad Dermatol. 2012 Sep;67(3):400-8
pubmed: 22088429
Am J Clin Dermatol. 2018 Nov;19(Suppl 1):31-39
pubmed: 30374901
Indian J Dermatol. 2014 May;59(3):271-4
pubmed: 24891659
J Oncol Pharm Pract. 2018 Apr;24(3):229-231
pubmed: 28436313
Dermatology. 2003;207(3):324-5
pubmed: 14571080
Skin Appendage Disord. 2020 Jan;6(1):32-36
pubmed: 32021859
J Clin Oncol. 2010 Mar 10;28(8):1351-7
pubmed: 20142600
Arch Dermatol. 2012 Dec;148(12):1399-402
pubmed: 22986691
Drugs. 2010 May 28;70(8):1059-78
pubmed: 20481659
Ann Oncol. 2008 Jan;19(1):92-8
pubmed: 17785764
Indian Dermatol Online J. 2019 May-Jun;10(3):251-255
pubmed: 31149566
J Gastrointest Oncol. 2013 Sep;4(3):319-27
pubmed: 23997943
Dermatol Res Pract. 2014;2014:734249
pubmed: 24723942